PDCD1 and non-small cell lung carcinoma: In patients with non-oncogene addicted advanced NSCLC, PD-1/PD-L1 blockade is currently the upfront standard of care as monotherapy, or in combination with chemotherapy, according to PD-L1 expression level [11], whereas treatment with anti PD-L1 durvalumab after curative chemoradiation has demonstrated to prolong survival in stage III unresectable NSCLC [12].